1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Egalet Ltd. – Product Pipeline Review – 2013

Egalet Ltd. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 35 pages

Egalet Ltd. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Egalet Ltd. - Product Pipeline Review - 2013” provides data on the Egalet Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Egalet Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Egalet Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Egalet Ltd. - Brief Egalet Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Egalet Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Egalet Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Egalet Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Egalet Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Egalet Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Egalet Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Egalet Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Egalet Ltd. and identify potential opportunities in those areas.

Table Of Contents

Egalet Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Egalet Ltd. Snapshot 5
Egalet Ltd. Overview 5
Key Information 5
Key Facts 5
Egalet Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Egalet Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Egalet Ltd. - Pipeline Products Glance 11
Egalet Ltd. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Egalet Ltd. - Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Egalet Ltd. - Drug Profiles 14
(hydrocodone + acetaminophen) IR 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
EGP-119 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
hydrocodone ER 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
hydromorphone hydrochloride 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
morphine sulfate ER 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
oxycodone hydrochloride ER 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Egalet Ltd. - Pipeline Products by Route of Administration 20
Egalet Ltd. - Pipeline Products By Mechanism of Action 21
Egalet Ltd. - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Financial Deals Landscape 23
Egalet Ltd., Deals Summary 23
Egalet Ltd., Pharmaceuticals and Healthcare, Deal Details 24
Venture Financing 24
Egalet Raises US$14.3 Million In Series B2 Financing 24
Egalet Secures US$19 Million In Series B Financing 26
Partnerships 28
Egalet Enters Into Co-Development Agreement With Schering-Plough 28
Licensing Agreements 29
Egalet Enters Into Licensing Agreement With Sandoz 29
Egalet Enters Into Licensing Agreement With RedHill Biopharma 30
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35



List of Tables

Egalet Ltd., Key Information 5
Egalet Ltd., Key Facts 5
Egalet Ltd. - Pipeline by Indication, 2013 7
Egalet Ltd. - Pipeline by Stage of Development, 2013 8
Egalet Ltd. - Monotherapy Products in Pipeline, 2013 9
Egalet Ltd. - Combination Treatment Modalities in Pipeline, 2013 10
Egalet Ltd. - Phase II, 2013 11
Egalet Ltd. - Phase I, 2013 12
Egalet Ltd. - Pre-Clinical, 2013 13
Egalet Ltd. - Pipeline By Route of Administration, 2013 20
Egalet Ltd. - Pipeline Products By Mechanism of Action, 2013 21
Egalet Ltd., Other Locations 22
Egalet Ltd., Deals Summary 23
Egalet Raises US$14.3 Million In Series B2 Financing 24
Egalet Secures US$19 Million In Series B Financing 26
Egalet Enters Into Co-Development Agreement With Schering-Plough 28
Egalet Enters Into Licensing Agreement With Sandoz 29
Egalet Enters Into Licensing Agreement With RedHill Biopharma 30



List of Figures

Egalet Ltd. - Pipeline by Indication, 2013 7
Egalet Ltd. - Pipeline by Stage of Development, 2013 8
Egalet Ltd. - Monotherapy Products in Pipeline, 2013 9
Egalet Ltd. - Combination Treatment Modalities in Pipeline, 2013 10
Egalet Ltd. - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.